GO:1904761 negative regulation of myofibroblast differentiation: Fibrosis Suppression, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904761 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of myofibroblast differentiation, a key step in fibrosis and tissue remodeling [1,3].
• Negative regulation of myofibroblast differentiation is essential for limiting excessive scar formation and pathological tissue stiffening in organs such as lung, heart, and skin [1,3,6].
• Key molecular players include SFRP1, SMAD7, miR-424, miR-192-5p, and autophagy-related pathways that intersect with TGF-beta and WNT signaling [1,3,4,6].
• Dysregulation of this process contributes to diseases including pulmonary fibrosis, hypertrophic scarring, and cancer-associated fibroblast activation [1,5,6].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise interrogation of genes that negatively regulate myofibroblast differentiation [3,4].
• Understanding this GO term supports development of anti-fibrotic therapies and strategies to modulate tumor microenvironment [5,7].
Description
Myofibroblasts are specialized contractile cells that play a central role in wound healing and tissue repair, but their persistent activation drives fibrosis and pathological remodeling in multiple organs [1,3]. The Gene Ontology term GO:1904761, negative regulation of myofibroblast differentiation, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of myofibroblast differentiation [1,3]. This regulatory process is critical for maintaining tissue homeostasis and preventing excessive scar formation. Research has identified diverse molecular mechanisms, including secreted frizzled-related protein 1 (SFRP1)-mediated inhibition of fibroblast invasion, SMAD7 induction that protects the pressure-overloaded heart, and microRNA-mediated regulation such as miR-424 during epithelial-to-mesenchymal transition [1,3,4]. These findings highlight the therapeutic potential of targeting negative regulators to treat fibrotic diseases and modulate cancer-associated fibroblasts [5,6]. Understanding GO:1904761 provides a framework for investigating how cells control the transition to a myofibroblast phenotype and how this control is lost in disease.
negative regulation of myofibroblast differentiation At A Glance
| GO ID | GO:1904761 |
|---|---|
| GO term | negative regulation of myofibroblast differentiation |
| Ontology | biological_process |
| Synonym | down regulation of myofibroblast differentiation; inhibition of myofibroblast differentiation; negative regulation of myofibroblast cell differentiation |
| Major function | Inhibits the conversion of precursor cells into contractile myofibroblasts, limiting fibrosis and pathological tissue remodeling. |
| Related processes | TGF-beta signaling, WNT signaling, autophagy, epithelial-to-mesenchymal transition (EMT), fibroblast activation. |
| Key regulators | SFRP1, SMAD7, miR-424, miR-192-5p, IL-17RA, autophagy-related proteins. |
| Disease relevance | Pulmonary fibrosis, cardiac fibrosis, hypertrophic scar, cancer-associated fibroblasts. |
What Is GO:1904761?
GO:1904761 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of myofibroblast differentiation. In other words, it includes molecular events that inhibit the conversion of precursor cells (such as fibroblasts, epithelial cells, or mesenchymal stem cells) into contractile, alpha-smooth muscle actin (ACTA2)-expressing myofibroblasts. This regulation can occur through secreted factors, intracellular signaling cascades, transcription factors, and non-coding RNAs that interfere with pro-differentiation pathways like TGF-beta and WNT [1,3,4,6].
Why Is negative regulation of myofibroblast differentiation Important in Cell Biology?
Negative regulation of myofibroblast differentiation is a critical brake on fibrosis, a pathological process characterized by excessive extracellular matrix deposition and organ dysfunction. Without proper negative regulation, persistent myofibroblast activation leads to tissue scarring, stiffness, and organ failure, as seen in idiopathic pulmonary fibrosis, heart failure, and chronic kidney disease [1,3]. Moreover, in cancer, cancer-associated fibroblasts (CAFs) often exhibit myofibroblastic features that promote immune evasion and tumor progression, making negative regulators potential therapeutic targets [5,7]. Thus, understanding GO:1904761 offers insights into fundamental mechanisms of tissue repair and provides a rationale for developing anti-fibrotic and immunomodulatory therapies.
• Prevents excessive scar formation and fibrosis in lung, heart, skin, and other tissues [1,3,6].
• Maintains tissue architecture and function by limiting pathological remodeling.
• Modulates tumor microenvironment by suppressing pro-tumorigenic cancer-associated fibroblasts [5,7].
• Involved in wound healing resolution and regeneration.
• Dysregulation contributes to hypertrophic scar and keloid formation.
• Provides therapeutic targets for anti-fibrotic drug development [1,3].
• Interplays with autophagy and senescence pathways in fibroblasts.
• Regulated by microRNAs and epigenetic mechanisms [4,6].
• Affects immune cell crosstalk and inflammation resolution.
• Critical for understanding epithelial-to-mesenchymal transition (EMT) in development and disease.
What Happens During negative regulation of myofibroblast differentiation?
Inhibition of TGF-beta signaling
In simple terms: Blocking the main signal that tells cells to become myofibroblasts.
TGF-beta is a master driver of myofibroblast differentiation. Negative regulation often involves interfering with TGF-beta signaling. For example, SMAD7 induction in cardiac fibroblasts protects the pressure-overloaded heart by inhibiting TGF-beta-mediated myofibroblast conversion. Similarly, SFRP1, a WNT antagonist, inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts, partly by modulating TGF-beta and WNT crosstalk. These mechanisms reduce the expression of myofibroblast markers such as ACTA2 and collagen.
MicroRNA-mediated repression
In simple terms: Small RNA molecules that put a brake on genes promoting myofibroblast differentiation.
MicroRNAs (miRNAs) can negatively regulate myofibroblast differentiation by targeting mRNAs encoding pro-fibrotic factors. miR-424 regulates myofibroblast differentiation during epithelial-to-mesenchymal transition (EMT) by targeting factors that promote the myofibroblast phenotype. Additionally, exosomes from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis via the miR-192-5p/IL-17RA/Smad axis, demonstrating that miRNA delivery can suppress myofibroblast differentiation. These miRNAs act post-transcriptionally to reduce protein levels of key inducers.
Autophagy and senescence modulation
In simple terms: Cellular recycling and aging processes that can influence fibroblast fate.
Autophagy has context-dependent roles in fibroblast biology. Autophagy drives fibroblast senescence through MTORC2 regulation, and senescent fibroblasts often exhibit reduced myofibroblast differentiation capacity. Thus, induction of autophagy may negatively regulate myofibroblast differentiation by promoting a senescent phenotype. This pathway intersects with mTOR signaling, a central regulator of cell growth and metabolism.
WNT/beta-catenin pathway antagonism
In simple terms: Turning off another growth signal that promotes myofibroblast formation.
WNT/beta-catenin signaling promotes myofibroblast differentiation in various contexts. Negative regulators such as SFRP1 act as decoy receptors to sequester WNT ligands, thereby inhibiting beta-catenin activation and downstream myofibroblast gene expression. The dynamic interplay between IL-1 and WNT pathways also regulates dermal adipocyte lineage cells during skin development and wound regeneration, indirectly affecting myofibroblast differentiation. Targeting WNT antagonists represents a strategy to block myofibroblast conversion.
Regulation by transcription factors and cofactors
In simple terms: Proteins that control which genes are turned on or off to prevent myofibroblast fate.
Transcription factors such as SMAD7 act as inhibitory SMADs that block TGF-beta-induced gene transcription. Other factors, such as those involved in adipocyte lineage commitment, can divert cells away from the myofibroblast lineage. These transcriptional regulators often work in concert with epigenetic modifiers to maintain a non-myofibroblast state. Their dysregulation can tip the balance toward fibrosis.
Key Genes Involved in GO:1904761 negative regulation of myofibroblast differentiation
The following genes and non-coding RNAs have been experimentally implicated in the negative regulation of myofibroblast differentiation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SFRP1 | Secreted WNT antagonist; inhibits fibroblast invasion and myofibroblast transition | Studied in lung fibrosis models; potential anti-fibrotic target |
| SMAD7 | Inhibitory SMAD; blocks TGF-beta signaling | Protects pressure-overloaded heart; cardiac fibrosis research |
| miR-424 | MicroRNA targeting pro-EMT factors | Regulates myofibroblast differentiation during EMT |
| miR-192-5p | Exosomal miRNA targeting IL-17RA/Smad axis | Attenuates hypertrophic scar fibrosis |
| IL-17RA | Receptor for IL-17; modulated by miR-192-5p | Involved in scar formation; target of exosomal therapy |
| MTORC2 | Kinase complex regulating autophagy and senescence | Autophagy-driven fibroblast senescence |
| ACTA2 | Alpha-smooth muscle actin; myofibroblast marker | Readout of myofibroblast differentiation [1,3] |
| COL1A1 | Type I collagen; major ECM component | Marker of fibrosis; negatively regulated [1,3] |
| WNT3A | WNT ligand promoting myofibroblast differentiation | Antagonized by SFRP1 |
| TGFB1 | Master pro-fibrotic cytokine | Target of negative regulation |
| IL1B | Interleukin-1 beta; modulates WNT pathway | Interplay in skin wound regeneration |
| ADIPOQ | Adipocyte marker; lineage diversion | Regulated by IL-1/WNT crosstalk |
| PPARG | Adipogenic transcription factor | May divert cells from myofibroblast fate |
| Huaier (proteoglycan) | Natural compound suppressing CAFs | Induces negative regulation in TNBC |
| Stromal cell markers | Various CAF subtypes | Associated with immune evasion in TNBC |
How Is negative regulation of myofibroblast differentiation Regulated?
The negative regulation of myofibroblast differentiation is itself tightly regulated at multiple levels. Extracellular signals such as WNT antagonists (SFRP1) and anti-inflammatory cytokines (IL-1) can inhibit pro-differentiation pathways [1,8]. Intracellularly, inhibitory SMADs (SMAD7) block TGF-beta receptor signaling. MicroRNAs (miR-424, miR-192-5p) provide post-transcriptional control by targeting mRNAs of pro-fibrotic genes [4,6]. Autophagy and mTORC2 signaling modulate fibroblast senescence, which can reduce myofibroblast differentiation capacity. Additionally, pharmacological agents like Huaier extract can suppress cancer-associated fibroblast activation, highlighting external regulation. These layers ensure that myofibroblast differentiation is restrained under homeostatic conditions and can be reactivated during injury.
negative regulation of myofibroblast differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SFRP1 | Pulmonary fibrosis | Sfrp1 knockout mouse; bleomycin-induced lung injury |
| SMAD7 | Cardiac fibrosis / heart failure | Cardiac-specific Smad7 overexpression or knockout mice |
| miR-192-5p | Hypertrophic scar | Exosome delivery in rabbit ear scar model |
| Huaier (target unknown) | Triple-negative breast cancer | Xenograft models with CAF co-injection |
| IL-17RA | Scar fibrosis | IL-17RA knockout mice; skin wound models |
Pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is characterized by persistent myofibroblast activation and excessive collagen deposition. SFRP1 has been shown to inhibit lung fibroblast invasion during transition to injury-induced myofibroblasts, suggesting that loss of SFRP1 contributes to IPF pathogenesis. Therapeutic strategies aimed at restoring negative regulation could slow disease progression.
Cardiac fibrosis and heart failure
In pressure-overloaded hearts, fibroblast Smad7 induction protects against remodeling by inhibiting TGF-beta-mediated myofibroblast differentiation. Reduced SMAD7 levels are associated with exacerbated cardiac fibrosis, highlighting the importance of negative regulation in heart disease.
Hypertrophic scar and skin fibrosis
Hypertrophic scars result from excessive myofibroblast activity. Exosomes from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis via the miR-192-5p/IL-17RA/Smad axis, demonstrating that enhancing negative regulation can reduce scar formation. The interplay between IL-1 and WNT pathways also regulates dermal adipocyte lineage cells during wound regeneration, influencing scar outcomes.
Cancer-associated fibroblasts and tumor microenvironment
In triple-negative breast cancer, cancer-associated fibroblasts (CAFs) often exhibit myofibroblastic features that promote immune evasion. Huaier-induced suppression of CAFs confers immunotherapeutic sensitivity, indicating that negative regulation of myofibroblast differentiation can remodel the tumor microenvironment and enhance immunotherapy.
From negative regulation of myofibroblast differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Sfrp1 increase myofibroblast differentiation? | Sfrp1 knockout mouse (constitutive or conditional) |
| Can a point mutation in Smad7 disrupt its inhibitory function? | Smad7 point-mutant knock-in mouse |
| Does overexpression of miR-424 suppress EMT-associated myofibroblast differentiation? | miR-424 overexpression lentivirus in epithelial cells |
| What is the effect of tagging endogenous SMAD7 with a fluorescent protein? | SMAD7-tagged knock-in via CRISPR |
| Can CRISPR activation of SFRP1 reduce fibrosis in vivo? | dCas9-VP64 activation in lung fibroblasts |
| Does knockout of IL-17RA mimic miR-192-5p effects? | IL-17RA knockout in scar fibroblasts |
How to Study the negative regulation of myofibroblast differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify pathways altered by negative regulators |
| Western blot | Protein levels of ACTA2, COL1A1, SMAD7 | Quantify myofibroblast differentiation |
| Immunofluorescence | Alpha-SMA stress fibers and localization | Tissue section analysis |
| Small RNA-seq | MicroRNA expression profiles | Discover regulatory miRNAs |
| Luciferase reporter assay | miRNA-target interaction | Validate miR-424 targeting |
| Collagen gel contraction | Contractile function of myofibroblasts | Functional readout |
| Exosome isolation and treatment | Delivery of regulatory miRNAs | Therapeutic potential |
| CRISPR screening | Identify genes affecting differentiation | Unbiased discovery of negative regulators |
Transcriptomic profiling (RNA-seq)
RNA sequencing can identify global changes in gene expression when negative regulators are manipulated. For example, comparing wild-type and Sfrp1-knockout fibroblasts reveals altered expression of myofibroblast markers and ECM components. This method helps uncover downstream pathways affected by negative regulation.
Protein analysis (Western blot, immunofluorescence)
Western blotting for ACTA2, collagen I, and SMAD7 can quantify myofibroblast differentiation status. Immunofluorescence for alpha-smooth muscle actin stress fibers provides spatial information in tissue sections. These methods are standard for validating negative regulation.
MicroRNA profiling and target validation
Small RNA sequencing and luciferase reporter assays can identify and validate miRNAs that negatively regulate myofibroblast differentiation, such as miR-424 and miR-192-5p [4,6]. Overexpression or inhibition of these miRNAs in cell models confirms their function.
Functional assays (invasion, contraction)
Collagen gel contraction assays measure myofibroblast contractility, a key functional output. Invasion assays assess fibroblast migration, which is often increased in fibrosis. These assays directly test the impact of negative regulators on myofibroblast behavior.
How CRISPR Can Be Used to Study GO:1904761 negative regulation of myofibroblast differentiation
Knockout
CRISPR knockout of candidate negative regulators (e.g., Sfrp1, Smad7) in fibroblasts or mice can test whether loss of function enhances myofibroblast differentiation. For example, Sfrp1 knockout mice show increased lung fibroblast invasion and myofibroblast transition after injury. Knockout studies are essential for establishing causality.
Point Mutation
Introducing specific point mutations (e.g., in Smad7 phosphorylation sites) can dissect signaling domains required for negative regulation. This approach helps distinguish between structural and functional roles of a protein. Point mutations can also mimic human disease variants.
Knock-in
Knock-in of tagged versions (e.g., GFP-SMAD7) allows real-time tracking of protein localization and dynamics during myofibroblast differentiation. Knock-in of reporter genes under endogenous promoters can monitor transcriptional activity of negative regulators.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can elevate levels of negative regulators such as SFRP1 or miR-424 to test their sufficiency in blocking myofibroblast differentiation [1,4]. Overexpression models are useful for therapeutic proof-of-concept.
How EDITGENE Supports negative regulation of myofibroblast differentiation Research
Researchers studying negative regulation of myofibroblast differentiation-related genes often need to determine whether a candidate gene is causally involved in suppressing the myofibroblast phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of myofibroblast differentiation research.
Frequently Asked Questions About negative regulation of myofibroblast differentiation
What is negative regulation of myofibroblast differentiation?
It is any biological process that stops, prevents, or reduces the differentiation of precursor cells into myofibroblasts, as defined by GO:1904761 [1,3].
What genes are involved in negative regulation of myofibroblast differentiation?
Key genes include SFRP1, SMAD7, miR-424, miR-192-5p, and IL-17RA, among others [1,3,4,6].
How does SFRP1 inhibit myofibroblast differentiation?
SFRP1 acts as a WNT antagonist, blocking WNT/beta-catenin signaling and thereby inhibiting fibroblast invasion and myofibroblast transition.
What is the role of SMAD7 in cardiac fibrosis?
SMAD7 induction in fibroblasts protects the pressure-overloaded heart by inhibiting TGF-beta-mediated myofibroblast differentiation.
Which microRNAs negatively regulate myofibroblast differentiation?
miR-424 and miR-192-5p have been shown to suppress myofibroblast differentiation through targeting pro-fibrotic pathways [4,6].
How is autophagy related to myofibroblast differentiation?
Autophagy drives fibroblast senescence via MTORC2, which can reduce the capacity for myofibroblast differentiation.
What diseases are associated with impaired negative regulation of myofibroblast differentiation?
Pulmonary fibrosis, cardiac fibrosis, hypertrophic scars, and cancer-associated fibroblast activation [1,3,5,6].
Can CRISPR be used to study negative regulation of myofibroblast differentiation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise interrogation of candidate genes [1,3,4].
What experimental models are used to study this process?
Common models include Sfrp1 knockout mice, Smad7 transgenic mice, and cell culture systems with miRNA overexpression [1,3,4].
How can I find genes that negatively regulate myofibroblast differentiation?
CRISPR library screening combined with bioinformatics can identify novel regulators in an unbiased manner.
Conclusion
GO:1904761, negative regulation of myofibroblast differentiation, represents a critical biological brake on fibrosis and pathological tissue remodeling. Research has elucidated diverse molecular mechanisms involving SFRP1, SMAD7, microRNAs, and autophagy, with direct implications for diseases such as pulmonary fibrosis, cardiac fibrosis, and cancer. Leveraging CRISPR-based models and EDITGENE's services can accelerate the discovery of new therapeutic targets and advance our understanding of this essential regulatory process.
References
- 1. Mayr CH et al.. 2024. Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts.. Eur Respir J 63(2) PMID: 38212077
- 2. Bernard M et al.. 2020. Autophagy drives fibroblast senescence through MTORC2 regulation.. Autophagy 16(11):2004-2016 PMID: 31931659
- 3. Humeres C et al.. 2024. Fibroblast Smad7 Induction Protects the Remodeling Pressure-Overloaded Heart.. Circ Res 135(3):453-469 PMID: 38899461
- 4. Xiao X et al.. 2015. Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition.. Arch Biochem Biophys 566:49-57 PMID: 25524739
- 5. Li C et al.. 2024. Huaier-induced suppression of cancer-associated fibroblasts confers immunotherapeutic sensitivity in triple-negative breast cancer.. Phytomedicine 135:156051 PMID: 39299097
- 6. Li Y et al.. 2021. Exosomes derived from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis by miR-192-5p/IL-17RA/Smad axis.. Stem Cell Res Ther 12(1):221 PMID: 33789737
- 7. Wu SZ et al.. 2020. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.. EMBO J 39(19):e104063 PMID: 32790115
- 8. Sun L et al.. 2023. Dynamic interplay between IL-1 and WNT pathways in regulating dermal adipocyte lineage cells during skin development and wound regeneration.. Cell Rep 42(6):112647 PMID: 37330908
